|Recent Exit||In Price/Share||Average Out Price/Share|
Scancell has developed novel therapeutic vaccine ‘platforms’ to treat cancer and infectious diseases. Following its successful IPO on AIM, the company’s share price rose significantly due to an increasing awareness of its lead compound, the SCIB1 anti-cancer vaccine which is based on its ImmunoBody® platform, and the development of a new technology platform called Moditope® that stimulate the production of killer cells.
Calculus Capital has partially exited Scancell through the placement of blocks of shares on AIM to meet institutional demand. The EIS Association voted this exit the Best EIS Investment Exit of 2012. We have subsequently successfully exited further investments in Scancell.